Ignite Creation Date:
2024-05-06 @ 9:11 AM
Last Modification Date:
2024-10-26 @ 12:11 PM
Study NCT ID:
NCT02920996
Status:
TERMINATED
Last Update Posted:
2024-04-11
First Post:
2016-09-29
Brief Title:
Merestinib In Non-Small Cell Lung Cancer And Solid Tumors
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Study Overview
Official Title:
A Phase II Study of Merestinib in Non-Small Cell Lung Cancers Harboring MET Exon 14 Mutations and Solid Tumors With NTRK Rearrangements
Status:
TERMINATED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Funding was pulled
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This research study is examining merestinib a targeted therapy as a possible treatment for non-small cell lung cancer NSCLC that was found to have a specific change in the MET gene a MET exon 14 mutation or as a treatment for solid tumors that have an alteration in the NTRK gene an NTRK1 2 or 3 rearrangement
Detailed Description:
This is an open-label phase II study of merestinib in patients with advanced NSCLC with a MET exon 14 mutation or patients with advanced cancer harboring an NTRK1 2 or 3 rearrangement Twenty patients with a MET mutation will be evaluated in a single-arm design A small separate cohort of 5 NTRK patients will be evaluated for exploratory purposes
Merestinib LY2801653 is a small molecule that has been shown in vitro to be a reversible type II ATP-competitive inhibitor of MET Pre-clinical testing also has shown merestinib to inhibit several other receptor tyrosine oncokinases including MST1R FLT3 AXL MERTK TEK ROS1 NTRK123 and DDR12 and the serinethreonine kinases MKNK12
Merestinib LY2801653 is a small molecule that has been shown in vitro to be a reversible type II ATP-competitive inhibitor of MET Pre-clinical testing also has shown merestinib to inhibit several other receptor tyrosine oncokinases including MST1R FLT3 AXL MERTK TEK ROS1 NTRK123 and DDR12 and the serinethreonine kinases MKNK12
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| I30-MC-E001 | OTHER | Eli Lilly and Company | None |